The purchase price, on cash- and debt-free basis, amounted to 65.7 MEUR, of which 24.1 MEUR was paid in 666,028 newly issued shares of series B in CELLINK at a price of 363.734 SEK per share (the “Consideration Shares”) and the reminder in cash. The price for the Consideration Shares has been determined by the volume weighted average price of CELLINK shares of series B on Nasdaq Stockholm under the last trading day preceding the completion date, i.e., on February 26, 2021. The Consideration Shares are expected to be registered by the Swedish Companies Registration Office during the month of March and will correspond to approximately 1.3 percent of the share capital and approximately 1.0 percent of the votes in CELLINK.
“With this strategic acquisition of Ginolis, we are further realizing CELLINK’s bioconvergence vision and to create the future of medicine by taking one step closer to the patients and improving healthcare around the world. CELLINK will be able to capitalize on several strong synergies within the field of microfluidics, diagnostics, and bioprinting. The cutting-edge modularity of the Ginolis robotics make the platforms ideal for scale-up of bioprinting systems and product offerings, enabling strategic and industrial expansion of our bioprinting capabilities to pharma and biotech customers. Ginolis’ advanced robotics and diagnostics automation for medical device and diagnostic industries can be fully integrated with CELLINK’s current offering and our present and future customers workflows and needs.” Erik Gatenholm, CEO, CELLINK.
For further information on the acquisition and about Ginolis, please see the press release which was published on February 15, 2021.
For further information, please contact:
|Erik Gatenholm, CEO
Phone (Sweden): +46 73 267 00 00
Phone (US): +1 (650) 515 5566
|Gusten Danielsson, CFO
Phone (Sweden): +46 70 991 86 04
Phone (US): +1 (857) 332 2138
The information was submitted for publication, through the agency of the contact persons set out above, on March 1, 2021 at 13.00 (CET).
Founded in 2016, CELLINK is the leading bioconvergence company in world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries. CELLINK’s products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,600 publications. CELLINK is creating the future of medicine. Visit cellink.com to learn more. CELLINK is listed on the Nasdaq Stockholm under CLNK B.